公开(公告)号：US20240307365A1

公开(公告)日：2024-09-19

申请号：US18577071

申请日：2022-07-22

申请人： Daewoong Pharmaceutical Co., Ltd.

发明人： Caroline Hee Lee ,  Da Jeong Bae ,  Min Jae Cho ,  Joon Seok Park

IPC分类号： A61K31/454 ,  A61K31/496 ,  A61K39/00 ,  A61P11/00 ,  A61P17/00

CPC分类号： A61K31/454 ,  A61K31/496 ,  A61P11/00 ,  A61P17/00 ,  A61K2039/505

摘要： The pharmaceutical composition according to the present invention can be usefully used for the prevention or treatment of systemic fibrosis.

公开(公告)号：US20240299404A1

公开(公告)日：2024-09-12

申请号：US18665688

申请日：2024-05-16

申请人： GlaxoSmithKline Intellectual Property (No.3) Limited

发明人： Antonios MATZOURANIS ,  Nathalie CHAURET ,  Denis GARCEAU

IPC分类号： A61K31/5377 ,  A61K31/4035 ,  A61K31/437 ,  A61K31/438 ,  A61K31/439 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61P17/04

CPC分类号： A61K31/5377 ,  A61K31/4035 ,  A61K31/437 ,  A61K31/438 ,  A61K31/439 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61P17/04

摘要： Methods of treating pruritus in a mammal with a P2X3 antagonist are disclosed. Said P2X3 antagonist is preferably a compound of Formula (I). Said pruritus may be associated with an inflammatory skin disorder, an infectious skin disease, an autoimmune skin disease or a pregnancy-related skin disease. The P2X3 antagonist may be administered by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or ophthalmic administration and may be used in conjunction with a NK-1 antagonist. The P2X3 antagonist acts by inhibiting pathological ATP release associated with hyperexcitability of afferent pruriceptive neurons, thus dampening peripheral hypersensitivity to itch via a broad mechanism independent on the pathological stimuli acting at itch receptors.

公开(公告)号：US20240294498A1

公开(公告)日：2024-09-05

申请号：US18564763

申请日：2022-05-27

申请人： Lunac Therapeutics Ltd

发明人： Richard James Foster ,  Sonia Abas Prades ,  James Nigel Ayres ,  Helen Philippou ,  Trevor Perrior ,  Alan Naylor ,  Philip Spencer Fallon ,  Anna Hopkins ,  Alicia Galvan Alvarez ,  Gabriel Negoita-Giras ,  John Joseph May ,  Daniel John Brough ,  Paolo Ricci

IPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5386 ,  A61K31/551 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/08 ,  C07D498/08

CPC分类号： C07D401/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/5386 ,  A61K31/551 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/08 ,  C07D498/08

摘要： The compounds of the invention are modulators of the Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

公开(公告)号：US20240293458A1

公开(公告)日：2024-09-05

申请号：US18443228

申请日：2024-02-15

申请人： NURIX THERAPEUTICS, INC.

发明人： Arthur T. SANDS ,  Neil F. Bence ,  Christoph W. Zapf ,  Frederick Cohen ,  Chenbo Wang ,  Thomas Cummins ,  Hiroko Tanaka ,  Hunter Shunatona ,  Mario Cardozo ,  Dahlia Weiss ,  Jennifa Gosling

IPC分类号： A61K35/17 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4545 ,  A61K33/243 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K38/19 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/107 ,  C07F5/02 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4545 ,  A61K33/243 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/39 ,  A61K39/3955 ,  A61K45/06 ,  A61N5/1001 ,  A61N5/1077 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D491/107 ,  C07F5/022 ,  C12N5/0636 ,  A61K2039/5152 ,  C12N2501/2302 ,  C12N2501/998 ,  C12N2501/999

摘要： Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

公开(公告)号：US20240293452A1

公开(公告)日：2024-09-05

申请号：US18431638

申请日：2024-02-02

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Evgeniy Eruslanov ,  Steven Albelda

IPC分类号： A61K35/15 ,  A61K31/454 ,  A61K38/19 ,  A61K38/21 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0787

CPC分类号： A61K35/15 ,  A61K31/454 ,  A61K38/193 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/39541 ,  A61K45/06 ,  A61P35/00 ,  C12N5/0642 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2300/00 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/599 ,  C12N2502/30

摘要： The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.

公开(公告)号：US20240287092A1

公开(公告)日：2024-08-29

申请号：US18437702

申请日：2024-02-09

申请人： The Trustees of Columbia University in the City of New York

发明人： Konstantin Petrukhin ,  Christopher Cioffi ,  Graham Johnson ,  Nicoleta Dobri ,  Emily Freeman ,  Ping Chen ,  Michael Conlon ,  Lei Zhu

IPC分类号： C07D498/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61P27/02 ,  C07D401/06 ,  C07D405/14 ,  C07D409/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D495/04

CPC分类号： C07D498/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61P27/02 ,  C07D401/06 ,  C07D405/14 ,  C07D409/06 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052 ,  C07D495/04

摘要： The present invention provides a compound having the structure:






wherein
R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or
C1-C4 alkyl;
R6 is H, OH, or halogen;
B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole,

wherein the heterobicycle is other than chloro substituted indole; and
the pyrazole, when substituted, is substituted with other than trifluoromethyl,

or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240285820A1

公开(公告)日：2024-08-29

申请号：US18569650

申请日：2022-06-19

申请人： ALPHA TAU MEDICAL LTD.

发明人： Yona Keisari ,  Itzhak Kelson ,  Vered Domankevich ,  Sara Del Mare Roumani ,  Robert Den ,  Fairuz Mansour ,  Ronen Segal ,  Margalit Efrati ,  Amit Shai ,  Yossi Nishri

IPC分类号： A61K51/12 ,  A61K9/00 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/454 ,  A61K31/4985 ,  A61K31/635 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K51/1282 ,  A61K9/0024 ,  A61K31/4245 ,  A61K31/437 ,  A61K31/454 ,  A61K31/4985 ,  A61K31/635 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

摘要： A substance which regulates immune-checkpoints for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the substance to the tumor, in one or more sessions, and implanting seeds (204) carrying radium-224 in the tumor for intra-tumoral alpha-emitter radiotherapy less than two weeks from administering the substance.

公开(公告)号：US20240285614A1

公开(公告)日：2024-08-29

申请号：US18433734

申请日：2024-02-06

申请人： Boundless Bio, Inc.

发明人： Anthony B. PINKERTON ,  Jacques MAUGER ,  Yen Pham Hong TRUONG ,  Camille REMEUR ,  Jérôme TOUM ,  Olivier MIRGUET

IPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/435 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4995 ,  A61K45/06 ,  C07D207/12 ,  C07D209/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08

CPC分类号： A61K31/496 ,  A61K31/404 ,  A61K31/435 ,  A61K31/438 ,  A61K31/454 ,  A61K31/4995 ,  A61K45/06 ,  C07D207/12 ,  C07D209/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08

摘要： Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

公开(公告)号：US12070503B2

公开(公告)日：2024-08-27

申请号：US17934056

申请日：2022-09-21

申请人： Dyve Biosciences, Inc.

发明人： Bruce J. Sand ,  Ryan R. Beal ,  Philippe H. Burnham

IPC分类号： A61K47/24 ,  A61F13/00 ,  A61F13/02 ,  A61K8/02 ,  A61K8/04 ,  A61K8/34 ,  A61K8/36 ,  A61K8/37 ,  A61K8/42 ,  A61K8/49 ,  A61K8/55 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K31/137 ,  A61K31/167 ,  A61K31/196 ,  A61K31/245 ,  A61K31/454 ,  A61K31/7004 ,  A61K33/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/28 ,  A61Q7/00 ,  A61Q19/08

CPC分类号： A61K47/24 ,  A61F13/00063 ,  A61F13/02 ,  A61K8/0291 ,  A61K8/042 ,  A61K8/34 ,  A61K8/36 ,  A61K8/37 ,  A61K8/42 ,  A61K8/4953 ,  A61K8/553 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/1075 ,  A61K31/137 ,  A61K31/167 ,  A61K31/196 ,  A61K31/245 ,  A61K31/454 ,  A61K31/7004 ,  A61K33/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/28 ,  A61Q7/00 ,  A61Q19/08

摘要： Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

公开(公告)号：US20240277856A1

公开(公告)日：2024-08-22

申请号：US18530017

申请日：2023-12-05

申请人： The Regents of the University of Mishigan

发明人： Jolanta GREMBECKA ,  Szymon KLOSSOWSKI ,  Jing DENG ,  Tomasz CIERPICKI ,  Hao LI ,  Hongzhi MIAO ,  Trupta PUROHIT ,  EunGi KIM

IPC分类号： A61K47/64 ,  A61K9/00 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4545 ,  A61K38/45 ,  A61K47/54 ,  A61P35/02 ,  C07D209/24 ,  C07D471/04

CPC分类号： A61K47/64 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/404 ,  A61K31/454 ,  A61K31/4545 ,  A61K38/45 ,  A61K47/545 ,  A61K47/556 ,  A61P35/02 ,  C07D209/24 ,  C07D471/04 ,  C12Y203/02

摘要： Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.